Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01904292
- Locations
- 🇺🇸
Hackensack University Medical Center; Pediatric Rheumatology, Hackensack, New Jersey, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology, Chicago, Illinois, United States
🇺🇸Cleveland Clinic Fndn, Cleveland, Ohio, United States
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01904279
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 19
- Registration Number
- NCT01791842
- Locations
- 🇫🇷
Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France
🇫🇷Service de rhumatologie, Hopital Edouard Herriot, HCL, Lyon, France
🇫🇷Service de rhumatologie, Hôpital Lariboisière, Paris, France
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)
- Conditions
- Interventions
- First Posted Date
- 2013-02-13
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 251
- Registration Number
- NCT01791153
- Locations
- 🇺🇸
Univ of Calif., Los Angeles; Rheumatology, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rheumatology Assoc. of S. Florida - Clinical Research Center, Boca Raton, Florida, United States
Efficacy of Tocilizumab in Primary Sjögren's Syndrome.
- Conditions
- Interventions
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2019-08-21
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 110
- Registration Number
- NCT01782235
- Locations
- 🇫🇷
Hôpitaux Universitaires de Strasbourg, Strasbourg, France
A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT01772316
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT01768572
- Locations
- 🇺🇸
Investigational Site Number 840033, Fort Lauderdale, Florida, United States
🇺🇸Investigational Site Number 840150, Lansing, Michigan, United States
🇺🇸Investigational Site Number 840022, Dallas, Texas, United States
A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT01734993
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT01734382
- Locations
- 🇮🇱
Meir Medical center, Pediatrics, Kfar Sava, Israel
🇮🇹Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina, Roma, Lazio, Italy
🇺🇸Children's Hospital Los Angeles; Division of Rheumatoogy, Los Angeles, California, United States
Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Ospedale San Raffaele
- Target Recruit Count
- 3
- Registration Number
- NCT01727206
- Locations
- 🇮🇹
San Raffaele Hospital, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.